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The effect of phenytoin, phenobarbitone, dexamethasone
and flurbiprofen on misonidazole neurotoxicity in mice
P.W. Sheldon, C. Clarke & K.B. Dawson
Radiobiology Unit, Department ofPhysics, Institute ofCancer Research, Sutton, Surrey SM2 5PX.
Summary Using a quantitative cytochemical technique for measuring ,B-glucuronidase activity in the
peripheral nerves of mice, we have investigated the effectiveness of four potential adjuncts for reducing the
dose limiting neurotoxicity of misonidazole (MISO) in the clinic.
Under the conditions used, the most effective adjunct was the steroid anti-inflammatory agent
dexamethasone. When given over the week previous to MISO treatment, this agent almost completely
eliminated the MISO neurotoxicity as determined at week 4 after commencement of MISO dosing. The
second most effective adjunct was phenytoin, the third flurbiprofen and the last adjunct, phenobarbitone, was
ineffective.
Dexamethasone, phenytoin and phenobarbitone all reduced the clearance half-life of MISO and hence the
drug exposure dose calculated as the area under the curve of MISO tissue concentration against time.
However, no correlation was evident with these parameters and MISO neurotoxicity in the mouse.
Dexamethasone, whilst affording protection against MISO toxicity, did not alter the radiosensitivity of the
anaplastic MT tumour.
It is now widely appreciated that the full radio-
sensitising potential of the nitroimidazole, misoni-
dazole (MISO), will not be realised clinically
because of dose-limiting peripheral neuropathy
(Dische et al., 1977; Urtasan et al., 1977). This has
prompted the search for ways to either develop less
toxic alternatives, or ameliorate the toxicity of
MISO itself. The developmental approach has
concentrated on nitroimidazoles of reduced octanol-
water partition coefficient: for it has been reported
that such compounds, though retaining their ability
to penetrate tumours, have a reduced capacity to
penetrate the central nervous system (Brown &
Workman, 1980). Indeed, we have previously
described a relationship between the partition
coefficient of nitroimidazoles and their neuro-
toxicity in mice (Clarke et al., 1982a). In the
present studies we have turned our attention to the
other approach for overcoming neurotoxicity, the
use of adjuncts to ameliorate the toxicity of MISO.
The incidence of MISO induced neurotoxicity in
man has been correlated with the exposure to the
drug as expressed by the area under the curve
(AUC) of plasma concentration with time (Dische
et al., 1979). Assuming the radiosensitising action
of MISO is dependent not on this total exposure
dose, but to the peak serum level obtainable at the
time of irradiation, one approach to reducing
neurotoxicity would be to combine MISO with an
agent that altered its pharmacokinetics towards a
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shorter half-life but unaltered peak concentration.
In mice, phenytoin and phenobarbitone have been
shown to achieve this by increasing the rate of
oxidative demethylation in the liver (Workman,
1979), Dexamethasone phosphate, though not
influencing the concentration of MISO in the blood
of mice, has been observed to reduce the concen-
tration in the brain, possibly by reducing the
cerebrovascular permeability and/or blood flow
(Workman, 1980a). Fortuitously, all these drugs
have been used as either anti-convulsants or anti-
inflammatory agents in a number of clinical trials
with MISO of patients with gliomas (Bleehen, 1980;
Wasserman et al., 1980).
We report here the influence of these drugs (i.e.
phenytoin, phenobarbitone and dexamethasone) on
the neurotoxicity of MISO, as assayed by
quantitative cytochemistry of the increased content
of the\ lysosomal enzyme, f-glucoronidase, in the
peripheral nerves of mice (Clarke et al., 1980). The
drugs were administered at doses similar to those
employed in the pharmacokinetic studies of
Workman (1979, 1980a). We have extended the
study to include the non-steroid anti-inflammatory
agent flurbiprofen which has been reported to
reduce the cytotoxic action of MISO in vitro,
possibly by inhibiting its catabolism to toxic
products (Millar et al., 1981). Further, because
dexamethasone has been reported to protect V-79
cells in vitro against x-irradiation (Millar & Jinks,
1981), an effect that would reduce any therapeutic
benefit accruing from combining this drug with
MISO treatment, we have investigated its effects on
the radiation response of a murine tumour in vivo.
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Materials and methods
Mice
Inbred, 8-10 week old, female, C57BI/Cbi mice
were used in the pharmacokinetic and neurotoxicity
studies and inbred, 6-8 week old, female, WHT/Cbi
mice were used in the radiation study.
Drugs
All drugs were dissolved in isotonic saline and
administered i.p. at 0.5ml per 25 g body wt. Unless
otherwise stated the doses employed were:
Phenytoin sodium salt (Sigma Chemical Co.) at
40 mgkg-1; Phenobarbitone sodium salt (British
Drug House Ltd.) at 80mgkg-1; Dexamethasone
disodium phosphate (Merck, Sharp & Dohme) at
0.5mgkg-1; Flurbiprofen sulphate (Boots Co. Ltd.)
at 25mgkg-1, and MISO (Roche Products Ltd.) at
300mgkg-1 (as a single dose in the pharmacolo-
gical studies, and daily for 5 days in the neuro-
toxicity studies).
The drug treatment schedules varied for each
experiment and are described in the text/figure
legends as appropriate. However, in all cases the
combination drugs were given prior to the MISO,
usually through the week previous to and/or the
same week as MISO treatment (in which case they
were given 2.5 h before each MISO dose.
Pharmacokinetics
Mice were sacrificed by carotid artery bleeding at
intervals from 15-240min after a single dose of
MISO. The blood and whole brain samples were
immediately frozen in liquid nitrogen and stored
prior to assay at -20°C. The concentrations of
MISO in the samples were determined by reverse
phase high-performance liquid chromatography
(HPLC) in a manner similar to that described by
Workman et al. (1978).
The measured tissue levels of MISO were in
accord with a single component open model and so
were fitted by non-linear least-square analysis
(Sampson, 1969) to the exponential function:
C=Ae-Pt
where C is drug tissue concentration, t is time after
dosing, A is a concentration constant (as
extrapolated back to time zero) and ,B the first
order disposition rate constant. The tissue terminal
phase half-life, tffl, was calculated in the form:
t-fl=Ln 2/f
The tissue exposure dose, AUC, was calculated in
the form:
AUC=A/fl
Neurotoxicity
The mice were sacrificed 4 weeks after the
commencement of MISO dosing and their tibial
nerves were assayed cytochemically for f,-
glucuronidase activity using a micro-densitometer
as described previously (Clarke et al., 1982b). The
resulting enzyme activities are expressed as
integrated optical density (OD) units x 103 and
increase in magnitude in line with the severity of
the neurotoxic response.
Radiation study
Mice were inoculated s.c. over the sacral region of
the back with anaplastic MT tumour cells. When
the resulting tumours attained a mean diameter of
6-7mm, the mice (except for control animals) were
given a single i.p. dose of 400mgkg-1 dexametha-
sone. At intervals of up to 24h thereafter, the
tumours were locally X-irradiated in a manner
similar to that described previously (Sheldon &
Hill, 1977). Eighteen hours later the tumours were
excised and their responses assayed by soft-agar
cloning (Sheldon et al., 1982).
Results
The increase in ,B glucuronidase activity in sciatic
nerves as a function of MISO dosage is shown in
Figure 1. At 80mgkg-1 per dose MISO produced
an insignificant increase in enzyme activity from
that observed in the untreated controls, but at
300mgkg-' per dose (as used here in most studies)
the activity was approximately double that of the
controls. This MISO-induced elevation in fi-
glucuronidase activity has previously been shown to
be a measure of neurotoxicity (Clarke et al., 1980).
The effects of phenytoin, phenobarbitone and
dexamethasone pretreatments on the pharmaco-
kinetics of MISO are shown in Table I. Under the
dosing regimes employed, none of the agents
altered the peak blood content of MISO from the
non-pretreated control value, but all three agents
did shorten the half-life. A similar pattern is evident
in the brain tissue although here dexamethasone
also reduced the peak brain content of MISO. Thus
in the hypothesis outlined above, all three agents
would, under the dosing conditions used, have the
potential for reducing MISO neurotoxicity.
It had been planned in the aforementioned
pharmacokinetic study to measure the demethylated
metabolite of MISO, DEMISO. However, this was
not possible because the DEMISO peak was not
clearly separable from the solvent front, although
the MISO and internal standard (Ro 07-0741)
peaks were well delineated. The inability to measureDRUG EFFECTS ON MISO NEUROTOXICITY 209
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Figure 1 The increase in ,B-glucuronidase activity in
sciatic nerves as a function of the daily MISO dose.
Data represents a total of 100 mice; s.e.'s are shown;
hatched area represents the s.e. range for the untreated
controls.
this metabolite is thought unlikely to be of
consequence to the conclusions reached in the
present work, for the expected DEMISO
component would be small at 10% of the total
nitroimidazole content (Workman, 1979; 1980a;
personal communication), and in this animal system
DEMISO is known to be considerably less toxic
than MISO (Adams et al., 1983).
The effects of MISO and/or the liver microsomal
enzyme inducers, phenytoin and phenobarbitone, on
the ,B-glucuronidase activity in the nerve are shown
in Figure 2. Each panel represents a discrete
experiment, and in both cases the MISO alone
treatment induced approximately a 100% increase
in enzyme activity relative to that measured in the
untreated control groups. Compared to the MISO
alone treated group shown in the left-hand panel,
pretreatment with phenytoin before the MISO
produced a significant decrease in enzyme activity
of -30%. This reduction in MISO induced enzyme
activity (to 29.8 integrated OD x 103) can by
reference to Figure 1 be equated to a reduction in
dose from 300 to 130mgkg-1, an apparent DMF
of 0.4. However, the phenytoin alone treatment
also produced a similar percentage decrease in
enzyme activity relative to the untreated controls.
Thus, if the ratios of the enzyme activity levels in
untreated control to MISO alone treated animals
are compared to phenytoin to phenytoin plus
MISO treated animals, there is no significant
TableI Concentrations ofMISOin blood and brain aftera single i.p. doseof300mgkg-1
following various pretreatment regimes.
Pretreatment Blood Brain
peakc 42 AUC peakc t4 AUC
(lgml- ) (min) (% CUgml- ) (min) (%
Nil 248 (±27) 69 (±7) 100 177 (±20) 54 (±4) 100
Phenytoina 292 (±53) 35 (±1) 69 139 (±18) 35 (±2) 62
Phenobarbitonea 303 (±28) 25 (±2) 63 169 (± 14) 29 (±2) 66
Phenobarbitone' 289 (±24) 56 (±9) 77 165 (± 17) 47 (±5) 78
Dexamethasone 299(±41) 47(±3) 84 94(±+l) 34(±2) 43
Phenytoin (40mgkg- per dose) and phenobarbitone (80mgkg-1 per dose) were
given daily for 5 days before MISO on either Day 8a or 12b. Dexamethasone
(0.5mgkg-1 per dose) was given daily for 8 days with the last dose 2- h before the
MISO. S.e.m.'s are shown in parenthesis.
Ct6peak" concentration is that measured at the earliest sampling time of 15min.
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Table II Effect of flurbiprofen on the MISO induced
increase in fl-glucuronidase activity in mouse nerves
f,-glucuronidase
Group (integrated OD x 103)+s.e.d
Expt. la Expt. 2b Expt. 3c
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Figure 2 Effect of MISO and/or phenytoin (a)
and/or phenobarbitone (b) on the ,B-glucuronidase
activity in peripheral nerves. Controls received no
treatment, phenytoin was administered on Days 1-8
(excluding 6-7) with MISO on Days 9-13, whilst
phenobarbitone was administered on Days 1-5 with
MISO on Days 8-12. S.e. are shown (4-8 mice per
group).
difference. Hence phenytoin may suppress the
neurotoxicity of MISO, but this particular assay
cannot be used to test it. The agent phenobarbitone
(right-hand panel), though given at a dose shown
above to induce changes in the pharmacokinetics of
MISO, induced no significant change in the enzyme
activities either relative to the untreated control
group, or when in combination with MISO relative
to the MISO alone treated group.
The effects of MISO and/or the non-steroid anti-
inflammatory agent flurbiprofen on the f,-
glucuronidase activity in the nerve are shown in
Table II. In all three experiments the MISO doses
were administered 2.5 h after flurbiprofen doses.
This interval was selected on account that it has
been reported to be effective in the flurbiprofen
protection against MISO cytotoxicity in vivo (Millar
et al., 1983). In the first experiment flurbiprofen in
combination with MISO produced no change from
the increased enzyme activity observed with MISO
alone. However, in this experiment a low MISO
dose was used which increased the enzyme activity
Untreated controls
Flurbiprofen
21.0+ 1.2 16.7+ 1.3 19.7+ 1.0
22.6+2.1
MISO 25.5+4.5 53.0+2.5 42.2+ 1.5
Flurbiprofen +MISO 27.8+8.4 44.6+2.8 36.4+2.8
aExpt. 1: 5 daily doses of 25mgkg-1 flurbiprofen
followed after 2.5 by 150mgkg-1 MISO.
bExpt. 2: 5 daily doses of 50mgkg ' flurbiprofen
followed after 2.5h by 300mgkg 1 MISO.
cExpt. 3: 12 daily doses of 20mgkg-1 flurbiprofen with
last 5 doses 2.5h before 300mgkg- MISO.
d4-8 mice per group.
by only 20% over that in control nerves from
untreated mice. In the second and third experiments
a higher MISO dose was employed which resulted
in about a 100% increase in enzyme activity over
that in control nerves. Under these conditions, the
addition of flurbiprofen did produce a small but
significant decrease of - 15% in MISO induced
enzyme activity. As flurbiprofen alone did not alter
the enzyme activity from that seen in control nerves
from untreated mice, this reduction in MISO-
induced enzyme activity (to 36.4 integrated
OD x 103) can by reference to Figure 1 be equated
to a reduction in dose from 300 to -210mgkg-1,
a DMF of 0.7.
The effect of MISO and/or the steroid anti-
inflammatory agent dexamethasone on the 1l-
glucuronidase activity in the nerve is shown in
Figure 3. Each panel represents a discrete
experiment. It can be seen from the results of the
first experiment (left-hand panel) that the MISO-
induced increase in enzyme activity was totally
suppressed by dexamethasone administered either at
a high dose for the week previous to MISO or at a
low dose for the week previous to as well as
throughout the same week as MISO treatment.
Conversely, in the second experiment (right-hand
panel) it can be seen that, relative to the MISO
alone treated group, the low dose of dexamethasone
has no effect if given only during the same week as
MISO, but suppresses the induced enzyme activity
by 60% if given over the week previous to MISO.
As the dexamethasone alone did not induce any
significant change in enzyme activity from that
observed for the untreated control mice, this
reduction in MISO-induced enzyme activity (to 27.7
integrated OD x 103) can by reference to Figure 1
be equated to a reduction in dose from 300 to
-120mgkg-1, a DMF of 0.4.
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Figure 4 shows the results from the study of
potential dexamethasone modification of the radio-
sensitivity of the anaplastic MT tumour. No radio-
protection was evident over the time course
employed, although the dose used was much greater
at 400mgkg-' than the 0.5mgkg-1 per dose
shown above as reducing MISO induced neuro-
toxicity.
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Figure 3 Effect of MISO and/or dexamethasone on
the ,B-glucuronidase activity in peripheral nerves.
Controls received no treatment, dexamethasone was
administered at 0.5mgkg-1 (h) or 0.25mgkg-l (1)
either the week previous (pre) to MISO (DEX on days
1-5, MISO on days 8-12), the same (sam) week as
MISO (DEX 2{h before MISO on days 1-5), or both
weeks (pre+sam) (DEX on days 1-5 and 8-12, MISO
on days 8-12). S.e. are shown (4-8 mice per group).
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Figure 4 Dexamethasone, when given as a single i.p.
dose of 400mgkg-1 from 30min to 24 h before a
single X-ray dose of 18 Gy, does not affect the radio-
sensitivity of the anaplastic MT tumour. Horizontal
bar represents geometric mean survival after X-rays
only (X), whilst (0) represents the responses of dexa-
methasone-treated mice. Each data point represents 2-
4 pooled tumours.
Discussion
The mechanism by which MISO produces its
neurotoxic effects is unknown. The toxicity could
stem from the drug itself, or a metabolite. It is
believed that under well oxygenated conditions
(such as found in the liver) the drug undergoes
oxidative metabolism to form the demethylated
metabolite DEMISO, whereas under poorly
oxygenated conditions (such as found in tumours)
it undergoes reductive metabolism to form the
amine (Workman, 1980b). Thus, any agent that
promotes or inhibits the metabolism of MISO
could interfere with its neurotoxic potential. We
have reported here our findings with four such
agents: phenytoin and phenobarbitone which are
believed to increase the oxidative metabolism of
MISO (Workman, 1979), and dexamethasone and
flurbiprofen, which are believed to inhibit its
reductive metabolism (Millar et al., 1983).
The effects of three of these agents (phenytoin,
phenobarbitone, dexamethasone) on the
pharmacology of MISO have been studied here
and, under the dosing regimes employed, none
altered the "peak" concentration of MISO in the
blood, but dexamethasone alone did result in a
small reduction in the brain "peak" (Table I).
However, all the agents did reduce the clearance
half-life in both tissues and hence resulted in
smaller drug exposures as expressed as areas under
the curve (AUC) of MISO tissue concentration as a
function of time. On the premise that the dose
limiting neuropathy of MISO in man is related to
the AUC (Dische et al., 1979), it follows that these
agents should have rendered MISO less neurotoxic
here. This was not always so, for although dexa-
methasone did reduce neurotoxicity (Figure 3),
phenobarbitone did not (Figure 2B) and the results
with phenytoin were equivocal (Figure 2A). Hence,
in the mouse AUC may not be the critical factor.
Indeed the importance of AUC in the clinic has
also been brought into question with the recent
observation that DEMISO, despite its reduced
AUC, appears no less neurotoxic than MISO
(Dische et al., 1982).
The dose of MISO used in the present studies
was chosen because, though sufficient to double the
,B-glucuronidase activity in nerves, it was thought
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akin to the clinical situation in that it was
insufficient to result in saturation of the liver
metabolic enzymes (Gibson, 1982). Nevertheless, as
discussed above, the liver microsomal enzyme
inducers, phenobarbitone and phenytoin, did
increase the clearance of MISO. However, this need
not have accounted for the reduced toxicity seen
after phenytoin pretreatment because a similar ratio
of reduced fJ-glucuronidase activity was seen in the
nerves of phenytoin alone to untreated control
mice, as in the nerves of phenytoin plus MISO to
MISO alone treated control mice (Figure 2A). Thus
the protection here by phenytoin against MISO
toxicity, though potentially useful if translatable to
the clinical situation, does not appear to have a
pharmacological basis. Perhaps phenobarbitone
does not possess this property, for it too modified
the pharmacokinetics of MISO but failed to reduce
its toxicity (Figure 2B). The use of an inappropriate
dosing regime is thought an unlikely explanation
for this failure; though the phenobarbitone was
only given through the week previous to that of
MISO treatment, and liver enzyme deinduction has
been reported to occur at a similar rate as
induction (Marshall & McLean, 1969), modified
pharmacokinetics were observed at the start and
(albeit to a lesser extent) the end of MISO treatment
(Table I).
It should be noted that whilst our pharmaco-
logical data are in general accord with those
reported by Workman (1979, 1980a), the dose of
dexamethasone we required to produce a reduction
in MISO brain levels was markedly lower, perhaps
because of the different mouse strains used. The
fact that the dexamethasone did result here in such
marked reductions in the AUCs for both brain and
blood would tend to indicate that the proposed
mechanism of an inhibition of MISO metabolism
seems unlikely. Jasani (1979) has reported that
dexamethasone causes capillary vasoconstriction
and reduced capillary permeability, and this could
account for the reduced levels of MISO seen in the
brain. Whatever the mechanism, dexamethasone did
prove very effective here at reducing MISO toxicity
as measured at week 4 after the commencement of
MISO dosing. However, it should be noted that
dexamethasone is known to delay the proliferation
responses associated with inflammation (Spain,
1961) and so, although not investigated here, the
agent could have delayed the enzyme changes
normally associated with the MISO induced nerve
damage. Indeed the enzyme fl-glucuronidase is a
marker for both Schwann cell increase and
macrophage infiltration (Hollinger & Rossiter,
1952; McCaman & Robins, 1959).
The data for the other anti-inflammatory agent,
the non-steroid flurbiprofen, also indicate a
reduction in the toxicity of MISO, but the effect is
smaller than seen with dexamethasone despite the
use of much higher drug doses. Unlike
dexamethasone, which was effective only when
given the week before MISO treatment,
flurbiprofen was also effective when given only
2.5h before each MISO dose.
In the present study, the effectiveness of the
agents at reducing the neurotoxicity of MISO are in
decreasing order, dexamethasone, phenytoin,
flurbiprofen and phenobarbitone. Caution should
be exercised in translating these observations in
mice to the clinic. Further, it should be borne in
mind that dexamethasone, apparently the most
effective agent here at reducing MISO neuro-
toxicity, may offer no therapeutic benefit since it
has also been reported to have the detrimental
effects of increasing the acute toxicity of MISO
(Workman, 1980a) and protecting V-79 cells in vitro
against X-irradiation (Millar & Jinks, 1981).
However, Millar did predict that such radio-
protection would only occur in those cells that
contained the appropriate steroid receptors, and
this may account for why Brock et al. (1983), whilst
observing radioprotection of V-79 cells, did not
observe it in three other in vitro cell lines. Similarly,
albeit in a limited study, we observed no radio-
protection by dexamethasone of the anaplastic MT
tumour in vivo (Figure 4). Consequently, giving
dexamethasone as an adjunct to MISO radio-
sensitiser therapy may be either beneficial or
detrimental depending on tumour cell type.
We conclude that under the conditions employed
here, dexamethasone, phenytoin, flurbiprofen, but
not phenobarbitone, were effective at reducing the
toxicity of MISO. However, this protection need
not have a pharmacological basis, at least not in
terms of blood or brain clearance half-life or AUC.
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